ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVYÂ (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lun